老年肺部感染导致中性粒细胞靶向迁移受损,辛伐他汀可改善
研究评估健康状态及下呼吸道感染、社区获得性肺炎、肺炎合并脓毒症时,年轻(<35岁)与老年(>60岁)患者血中性粒细胞的迁移准确性,并观察辛伐他汀的体外作用,随后在健康老年人中开展双盲随机临床试验验证。结果显示老年患者中性粒细胞迁移准确性随感染性肺部损伤严重程度加重而下降,6周时未恢复;辛伐他汀在老年及轻至中度感染时可挽救迁移能力(老年人需高剂量),但严重脓毒症时无效。在健康老年人的双盲随机临床试验中,高剂量(80 mg)辛伐他汀改善中性粒细胞迁移准确性,且未妨碍其他中性粒细胞功能。辛伐他汀改变表面黏附分子表达与活性,促进老年人准确迁移。作者认为上述结果支持其作为肺部感染早期干预的潜在用途。
要点
- 老年(>60岁)患者中性粒细胞迁移准确性随感染性肺部损伤严重程度加重而恶化,且6周时未恢复。
- 体外实验中辛伐他汀可挽救老年及轻至中度感染时的中性粒细胞迁移,但严重脓毒症时无效。
- 健康老年人双盲随机临床试验中,高剂量(80 mg)辛伐他汀改善中性粒细胞迁移准确性,且未妨碍其他中性粒细胞功能。
- 辛伐他汀通过改变表面黏附分子表达与活性促进老年人准确迁移。
- 作者认为结果支持辛伐他汀作为肺部感染早期干预的潜在用途,而非用于严重脓毒症。
适用人群与场景
- 血液中性粒细胞取自年轻(<35岁)与老年(>60岁)患者,覆盖健康状态、下呼吸道感染、社区获得性肺炎及肺炎合并脓毒症。
- 体外实验评估辛伐他汀对上述中性粒细胞迁移的作用;另在健康老年人中开展双盲随机临床试验验证。
处置流程与药物剂量
- 体外实验:对年轻(<35岁)与老年(>60岁)患者的中性粒细胞,在有或无辛伐他汀条件下评估迁移准确性。
- 健康老年人双盲随机临床试验:高剂量(80 mg)辛伐他汀改善中性粒细胞迁移准确性,未妨碍其他中性粒细胞功能。
研究设计与关键结果
- 研究类型:体外中性粒细胞迁移实验加健康老年人双盲随机临床试验;评估年轻(<35岁)与老年(>60岁)患者在健康、下呼吸道感染、社区获得性肺炎及肺炎合并脓毒症时的中性粒细胞迁移准确性。
- 老年中性粒细胞迁移准确性随感染性肺部损伤严重程度增加而恶化,6周时未恢复。
- 辛伐他汀在老年及轻至中度感染时挽救中性粒细胞迁移(老年人需高剂量),但在更严重的脓毒症时无效。
- 健康老年人双盲随机临床试验中,高剂量(80 mg)辛伐他汀改善中性粒细胞迁移准确性,未妨碍其他中性粒细胞功能。
- 辛伐他汀改变表面黏附分子表达与活性,促进老年人准确迁移。
证据类型、等级与局限
- 证据类型:体外实验加健康老年人双盲随机临床试验;临床试验注册号2011-002082-38。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对老年(>60岁)肺部感染患者,中性粒细胞迁移准确性受损且6周未恢复,可能参与不良结局,提示感染期间及感染后需关注这一持续缺陷。
- 作者认为辛伐他汀可考虑作为肺部感染的早期干预,依据是其在健康及轻至中度感染中改善中性粒细胞迁移;严重脓毒症时体外无效,不适用于该情形。
- 健康老年人中高剂量(80 mg)辛伐他汀改善迁移准确性且未妨碍其他中性粒细胞功能,但该结果来自健康老年人试验,不能直接作为感染患者用药推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Dysregulated neutrophil functions with age and sepsis are described. Statins are associated with improved infection survival in some observational studies, but trials in critically ill patients have not shown benefit. Statins also alter neutrophil responses in vitro.
OBJECTIVES: To assess neutrophil migratory accuracy with age during respiratory infections and determine if and how a statin intervention could alter these blunted responses.
METHODS: The migratory accuracy of blood neutrophils from young (aged <35 yr) and old (aged >60 yr) patients in health and during a lower respiratory tract infection, community-acquired pneumonia, and pneumonia associated with sepsis was assessed with and without simvastatin. In vitro results were confirmed in a double-blind randomized clinical trial in healthy elders. Cell adhesion markers were assessed.
MEASUREMENTS AND MAIN RESULTS: In vitro neutrophil migratory accuracy in the elderly deteriorated as the severity of the infectious pulmonary insult increased, without recovery at 6 weeks. Simvastatin rescued neutrophil migration with age and during mild to moderate infection, at high dose in older adults, but not during more severe sepsis. Confirming in vitro results, high-dose (80-mg) simvastatin improved neutrophil migratory accuracy without impeding other neutrophil functions in a double-blind randomized clinical trial in healthy elders. Simvastatin modified surface adhesion molecule expression and activity, facilitating accurate migration in the elderly.
CONCLUSIONS: Infections in older adults are associated with prolonged, impaired neutrophil migration, potentially contributing to poor outcomes. Statins improve neutrophil migration in vivo in health and in vitro in milder infective events, but not in severe sepsis, supporting their potential utility as an early intervention during pulmonary infections. Clinical trial registered with www.clinicaltrialsregister.eu (2011-002082-38).
参考来源
- Sapey E, Patel JM, Greenwood HL, et al. Pulmonary Infections in the Elderly Lead to Impaired Neutrophil Targeting, Which Is Improved by Simvastatin. Am J Respir Crit Care Med. 2017. PMID: 28657793. doi:10.1164/rccm.201704-0814OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。